Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00029328

Enrollment

Registered

2002-01-11

Start date

2001-09-30

Completion date

2003-09-30

Last updated

2015-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis Obliterans, Pneumonia, Respiratory Distress Syndrome, Adult

Keywords

TNFR-Fc fusion protein, Stem Cell Transplantation, Transplantation, Homologous, Respiratory Function Tests

Brief summary

The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation.

Detailed description

Over the last 2 decades, allogeneic bone marrow transplantation (BMT) has emerged as an important treatment option for a number of malignant and non-malignant disorders. Unfortunately, pulmonary dysfunction remains a frequent and severe complication of allogeneic BMT. One of the main chemicals felt to cause lung damage is Tumor Necrosis Factor (TNF). Etanercept is an experimental drug that attempts to block TNF lung damage. Patients will undergo blood tests, x-rays, and a bronchoscopy with broncho-alveolar lavage prior to treatment with etanercept to check for infection. If no infection is evident after 24 hours, the etanercept will be started and administered twice weekly for 4 weeks by subcutaneous injection. There will be weekly blood tests and bronchoscopy after the last drug dose.

Interventions

DRUGetanercept

Study design

Allocation

NON_RANDOMIZED

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Months to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of acute idiopathic pneumonia syndrome (IPS) or sub-acute lung injury * At least 1 year of age for IPS stratum * At least 6 years of age for sub-acute lung injury stratum and able to perform formal pulmonary function testing * At least 14 days since prior treatment with an investigational drug for graft-versus-host disease * Previously treated with allogeneic stem cell or bone marrow transplantation for primary disease

Exclusion criteria

* Documented evidence of active systemic or pulmonary infection * Cardiogenic failure as cause of pulmonary dysfunction * Known hypersensitivity to etanercept * Currently receiving dialysis * Currently receiving inotropic medications except dopamine * Pregnant or nursing

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026